Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 25, Number 8—August 2019
CME ACTIVITY - Research

Retrospective Cohort Study of Lassa Fever in Pregnancy, Southern Nigeria

Sylvanus OkogbeninComments to Author , Joseph Okoeguale, George Akpede, Andres Colubri, Kayla G. Barnes, Samar Mehta, Reuben Eifediyi, Felix Okogbo, Joseph Eigbefoh, Mojeed Momoh, Mojeed Rafiu, Donatus Adomeh, Ikponmwosa Odia, Chris Aire, Rebecca Atafo, Martha Okonofua, Meike Pahlman, Beate Becker-Ziaja, Danny Asogun, Peter Okokhere, Christian Happi, Stephan Günther, Pardis C. Sabeti, and Ephraim Ogbaini-Emovon
Author affiliations: Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Nigeria (S.A. Okogbenin, J. Okoeguale, G. Akpede, R. Eifediyi, F. Okogbo, J. Eigbefoh, M. Momoh, M. Rafiu, D. Adomeh, I. Odia, C. Aire, R. Atafo, M. Okonofua, D. Asogun, P. Okokhere, E. Ogbaini-Emovon); Ambrose Alli University Faculty of Clinical Science, Ekpoma, Nigeria (S.A. Okogbenin, G. Akpede, D. Asogun, P. Okokhere),; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA (A. Colubri, K.G. Barnes, S. Mehta, P.C. Sabeti); Harvard University, Cambridge (A. Colubri, P.C. Sabeti); Beth Israel Deaconess Medical Center, Boston, Massachusetts (S. Mehta); Bernhard Nocht Institute for Tropical Medicine and German Centre for Infection Research, Partner Site, Hamburg, Germany (M. Pahlman, B. Becker-Ziaja, S. Günther); Department of Biological Sciences and African Center of Excellence for Genomics of Infectious Diseases, Redeemer’s University, Ede, Nigeria (C. Happi); Harvard School of Public Health, Boston (P.C. Sabeti)

Main Article

Table 1

Demographic characteristics and outcomes observed in a retrospective cohort study of Lassa fever in pregnancy conducted at Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria, January 2009–March 2018*

Year of diagnosis Maternal age, y Fetal gestational age, wks Maternal clinical status† Fetal status Maternal outcome Perinatal outcome
2009 24 10 Severe Dead Died NA
2009 35 6 Severe Dead Died NA
2009 28 12 Severe Dead Survived NA
2009 29 7 Severe Dead Survived NA
2009 31 22 Severe Dead Died NA
2010 16 33 Mild† Alive Survived Survived
2010 26 32 Severe Dead Died NA
2010 37 11 Severe Dead Died NA
2010 30 31 Severe Dead Survived NA
2011 26 24 Severe Dead Died NA
2011 26 9 Severe Dead Died NA
2011 32 36 Mild Alive Survived Survived
2011 27 11 Severe Dead Survived NA
2012 39 35 Mild Alive Survived Died 3 d after birth
2012 26 33 Mild Alive Survived Survived
2013 25 8 Severe Dead Died NA
2013 30 31 Mild Alive Survived Survived
2013 31 29 Mild Alive Died Died at 38 wks
2013 32 10 Severe Dead Survived NA
2014 18 33 Mild Dead Survived NA
2014 28 12 Severe Dead Survived NA
2015 26 28 Mild Alive Survived Survived
2016 33 27 Mild Alive Survived Survived
2017 35 34 Mild Alive Survived Survived
2017 32 29 Mild Alive Survived Twins; 1 died at 37 wks, 1 survived
2017 23 32 Severe Dead Died NA
2017 24 31 Mild Alive Survived Survived
2017 36 25 Severe Dead Died NA
2018 33 29 Mild Alive Survived Survived
2018 32 33 Severe Alive Survived Survived

*NA, not applicable.
†Severe maternal outcome defined as any of the following: convulsions, irrational behavior, coma, extravaginal bleeding, or oliguria (<0.5 mL/kg/h for ≥6 h). Mild maternal presentation defined as the absence of all of these features.

Main Article

Page created: July 16, 2019
Page updated: July 16, 2019
Page reviewed: July 16, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external